18.12

2.60% 0.46

After Hours: 18.12

Urogen Pharma Ltd (URGN)

Overview News Price History Option Chain Financials Discussions Forecast

Urogen Pharma Ltd stock is traded at $18.12, with a volume of 346.79K. It is up +2.60% in the last 24 hours and down -12.34% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Previous Close:

$17.66

Open:

$17.69

24h Volume:

346.79K

Relative Volume:

0.46

Market Cap:

$882.12M

Revenue:

$109.79M

Net Income/Loss:

$-153.49M

P/E Ratio:

-5.6452

EPS:

-3.2098

Net Cash Flow:

$-172.59M

1W Performance:

-1.95%

1M Performance:

-12.34%

6M Performance:

+4.98%

1Y Performance:

+58.95%

1-Day Range:

$17.69

$18.37

1-Week Range:

$16.70

$19.03

52-Week Range:

$3.42

$30.00

Urogen Pharma Ltd Stock (URGN) Company Profile

Name

Urogen Pharma Ltd

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

972 9 770 7601

Address

9 HA'TA'ASIYA ST, RA'ANANA

Employee

291

Twitter

@UroGenPharma

Next Earnings Date

2025-03-10

Latest SEC Filings

URGN's Discussions on Twitter

Compare URGN vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
URGN Urogen Pharma Ltd	18.12	859.73M	109.79M	-153.49M	-172.59M	-3.2098
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-19-25	Initiated	Piper Sandler	Overweight
Jun-16-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-22-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-16-25	Initiated	Scotiabank	Sector Outperform
Feb-19-25	Resumed	Ladenburg Thalmann	Buy
Aug-22-24	Initiated	Guggenheim	Buy
Feb-08-23	Downgrade	Jefferies	Buy → Hold
Apr-27-22	Initiated	Berenberg	Buy
Apr-16-20	Reiterated	H.C. Wainwright	Buy
Apr-13-20	Reiterated	H.C. Wainwright	Buy
Jan-09-20	Initiated	National Securities	Neutral
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy
Nov-15-17	Reiterated	Oppenheimer	Outperform
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

View All

Urogen Pharma Ltd Stock (URGN) Latest News

04:48 AM

Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com

04:48 AM

09:15 AM

Veteran cancer researcher Mark joins Urogen Pharma to drive progress in urologic oncology - Traders Union

09:15 AM

Mar 24, 2026

Forecast Cut: Can UroGen Pharma Ltd keep up with sector leaders2026 Retail Activity & Low Risk High Win Rate Stock Picks - baoquankhu1.vn

Mar 24, 2026

Mar 20, 2026

How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities - Yahoo Finance

Mar 20, 2026

Mar 19, 2026

Live UroGen Pharma Ltd. (URGN) Technical Analysis - Traders Union

Mar 19, 2026